Abbott Plans $8.5 Billion Nutrition Spinoff as Pediatric Growth Outpaces Adult Brands
Abbott intends to separate its global Nutrition business into a standalone publicly traded company, carving out a roughly $8.5 billion portfolio of infant formula, pediatric nutrition and adult medical-nutrition brands. The company announced the plan on October 21, 2026, and said it expects to complete a tax-free distribution of shares to Abbott investors by the end of 2027, subject to regulatory approvals, an effective Form 10 registration statement and final approval by Abbott’s board.
The separation would create one of the world’s larger focused nutrition businesses: about 16,000 employees, 14 manufacturing sites and brands including Similac, PediaSure, Pedialyte, Glucerna and Ensure. Abbott said Daniel Salvadori, currently executive vice president of its Nutrition business, is expected to lead the new company as chief executive.
The headline numbers come from Abbott’s separation announcement and its investor presentation. The proposal is not a completed transaction. Nutrition remains part of Abbott while management prepares the filing, capital structure, governance and operational separation.
A large carve-out, not a peripheral brand sale
Abbott reported $36.77 billion in sales for the first nine months of 2026, including $6.423 billion from Nutrition. That means Nutrition contributed about 17.5% of group sales over the period—roughly one dollar in every six. In the third quarter alone, Nutrition generated $2.262 billion, or 17.4% of Abbott’s $13.013 billion total.
Those calculations matter because the proposed transaction is much larger than a disposal of a slow-growing product line. It would move a global manufacturing network, regulatory responsibilities, specialist clinical relationships and household brands into a company whose capital allocation will be concentrated on nutrition.
Abbott’s presentation puts the Nutrition company’s pro forma adjusted operating margin at about 18%. The remaining Abbott—medical devices, diagnostics and branded generic pharmaceuticals—would have about $42 billion in annual sales, approximately 106,000 employees and an adjusted operating margin near 25%. Abbott forecasts that the separation would improve the remaining company’s sales-growth profile by 50 to 100 basis points and its adjusted operating margin by about 100 basis points. Those are management projections, not results already achieved.
The growth picture is improving, but not uniformly
Abbott’s third-quarter results show why investors should separate a strong recent quarter from the longer year-to-date record. Worldwide Nutrition sales rose 5.1% as reported in the third quarter, yet sales for the first nine months were still 1.3% below the same period of 2025.
The mix inside the division also diverged. Third-quarter pediatric nutrition sales rose 8.8% to $1.063 billion, while adult nutrition sales increased 2.0% to $1.199 billion. Across the first nine months, pediatric sales were down 0.8% and adult sales were down 1.7%. U.S. Nutrition sales for the nine-month period fell 4.5%, whereas international sales rose 1.1% on a reported basis.
For the future standalone company, that split will shape the investment case. Pediatric formula and specialized products can carry strong brand and clinical value, but they also face strict quality controls, country-specific regulation and politically sensitive questions about infant-feeding markets. Adult nutrition has a different demand base, tied to ageing populations, medical recovery and everyday wellness, but Abbott’s latest figures show slower near-term growth in that lane.
What changes—and what does not—before 2028
There is no immediate change to the availability, labeling or ownership of Abbott’s nutrition brands. Manufacturing plants, employees, distributors and customers remain within Abbott during the separation process. Consumers should not read the announcement as a product withdrawal or a change to formula supply.
The eventual strategic change could be substantial. A pure-play nutrition company can direct its balance sheet and management attention toward plant modernization, quality systems, product development and distribution without competing internally with fast-growing medical-device programs. It may also make operating performance easier for investors, suppliers and customers to assess.
Independence also removes the buffer of a much larger diversified parent. A nutrition-only company would be more directly exposed to dairy, vegetable-oil, packaging, freight and energy costs, as well as swings in birth rates, consumer purchasing power and reimbursement for clinical products. Whether sharper focus outweighs that concentration will depend on the capital structure and operating agreements disclosed later.
Abbott has not yet disclosed the new company’s name, ticker, headquarters, board, debt allocation, detailed plant list or the final treatment of every asset and liability. It has also not quantified transaction charges. Those omissions are normal at this stage, but they are material: the forthcoming Form 10 should provide the first full standalone financial statements, segment risks, separation agreements and management discussion.
The supply-chain stakes
Nutrition manufacturing is not interchangeable with ordinary packaged-food production. Infant formula and medical-nutrition products require tightly controlled ingredients, validated processing, hygienic filling, traceability and regulatory oversight. Fourteen plants under a focused company would represent a consequential physical network, but Abbott has not announced plant closures, expansions or sourcing changes as part of the transaction.
The correct near-term reading is therefore structural rather than operational: Abbott is preparing to change who owns and finances the network, not announcing an immediate change in what the network produces. Suppliers and customers should watch for three sets of details over the next year—manufacturing and transitional-service agreements, the standalone balance sheet and debt burden, and capital-expenditure priorities by product and region.
Dividend policy is another signal. Abbott said it expects the combined dividend paid by Abbott and the new Nutrition company immediately after separation to equal Abbott’s dividend at the time of the transaction. That is an intention, not a guaranteed future payout, and each board would control dividends after the separation.
What could delay or change the plan
The end-2027 target leaves a long execution window. Regulatory review, tax rulings, market conditions, separation readiness or a board decision could alter the timetable or prevent completion. Abbott’s filing explicitly treats the transaction’s expected benefits and timing as forward-looking statements.
For food-industry readers, the most useful next evidence will not be another broad strategic promise. It will be the Form 10’s audited carve-out accounts, cash-flow profile, debt, geographic revenue exposure, disclosed capacity and investment commitments. Those details will show whether the new company begins life primarily as a stable cash-generating branded-food group, a growth platform for specialized nutrition, or a mixture of both.
Methodology and sources
Agrilinkage calculated Nutrition’s share of Abbott sales from the figures in Abbott’s October 21, 2026 quarterly results. Transaction terms, timetable, workforce, manufacturing footprint and leadership come from Abbott’s official announcement, investor presentation and Form 8-K materials. Company forecasts are identified as such. No interviews or firsthand product tests were used.
Comments